Drug Profile
Dasotraline - Sumitomo Pharma
Alternative Names: DSP-225289; SEP 225289; SEP-0225289; SEP-225289-HCI; SEP-289Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Sepracor
- Developer Sepracor; Sumitomo Pharma; Sumitomo Pharma America
- Class Amines; Antidepressants; Cyclobutanes; Naphthalenes; Small molecules; Tetrahydronaphthalenes
- Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Attention-deficit hyperactivity disorder; Binge-eating disorder; Major depressive disorder
Most Recent Events
- 27 Feb 2023 Planned Prescription Drug User Fee Act (PDUFA) date for Attention-deficit hyperactivity disorder (In adolescents, In children, In adults) in USA (PO) is 2018-08-30
- 01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma
- 28 Feb 2021 No recent reports of development identified for phase-I development in Attention-deficit-hyperactivity-disorder in Japan (PO, Capsule)